Arcutis legal chief sells 9,989 shares

Arcutis Biotherapeutics’ EVP and Chief Legal Officer sold 9,989 shares under a Rule 10b5-1 plan and now directly holds 116,182 shares.

Rhea-AI Filing Summary

Arcutis Biotherapeutics, Inc. (ARQT) reported that EVP and Chief Legal Officer Masaru Matsuda sold 9,989 shares of common stock on September 8, 2026 in an open‑market or private transaction at a weighted average price of $25.03 per share, with individual trade prices ranging from $25.00 to $25.12. Following this sale, he directly holds 116,182 shares of Arcutis common stock. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 5, 2026, with a plan end date of September 1, 2027.

Insider Trade Summary 10b5-1

Net Seller: 9,989 shares

Net Sell 1 txn

Insider Matsuda Masaru

Role See Remarks

Sold 9,989 shs ($250K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	9,989	$25.0261	$250K

Holdings After Transaction: Common Stock — 116,182 shares (Direct)

Footnotes (2)

1. F1. The transactions reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on June 5, 2026, by the Reporting Person, with a plan end date of September 1, 2027.
2. F2. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.12, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Key Figures

Shares sold: 9,989 shares Weighted average sale price: $25.0261 per share Price range of sales: $25.00–$25.12 per share +3 more

6 metrics

Shares sold 9,989 shares Common stock sale reported for September 8, 2026

Weighted average sale price $25.0261 per share Average price for the 9,989 shares sold

Price range of sales $25.00–$25.12 per share Range of prices for multiple sale transactions on September 8, 2026

Shares held after transaction 116,182 shares Direct ownership of Masaru Matsuda after the reported sale

Rule 10b5-1 plan adoption date June 5, 2026 Adoption date of trading plan covering the reported sale

Rule 10b5-1 plan end date September 1, 2027 Plan end date for the trading plan governing the transaction

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, open market or private transaction

3 terms

Rule 10b5-1 trading plan regulatory

"transactions reported in this Form 4 was effected pursuant to a 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The price reported in Column 4 is a weighted average sale price."

open market or private transaction financial

"Sale in open market or private transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ARQT report for Masaru Matsuda?

Arcutis Biotherapeutics reported that EVP and Chief Legal Officer Masaru Matsuda sold 9,989 shares of common stock on September 8, 2026 in a reported open‑market or private transaction.

At what price were the ARQT shares sold in this Form 4 filing?

The reported sale had a weighted average price of $25.0261 per share. A footnote states the shares were sold in multiple transactions at prices ranging from $25.00 to $25.12 per share, inclusive.

How many ARQT shares does Masaru Matsuda hold after the reported sale?

After the sale, Masaru Matsuda directly holds 116,182 shares of Arcutis Biotherapeutics common stock, as reported in the Form 4.

Was the ARQT insider sale made under a Rule 10b5-1 trading plan?

Yes. The filing states the transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Masaru Matsuda on June 5, 2026, with a plan end date of September 1, 2027.

What is the role of the insider involved in this ARQT Form 4?

The reporting person, Masaru Matsuda, serves as EVP, Chief Legal Officer of Arcutis Biotherapeutics, according to the remarks in the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/10/2026 - 07:25 PM Accepted by SEC EDGAR 09/10/2026 - 07:24 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Matsuda Masaru

(Last) (First) (Middle)

C/O ARCUTIS BIOTHERAPEUTICS, INC.

3027 TOWNSGATE ROAD, SUITE 300

(Street)

WESTLAKE VILLAGE CALIFORNIA 91361

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arcutis Biotherapeutics, Inc. [ ARQT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/08/2026		S(1)		9,989	D	$25.0261(2)	116,182	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on June 5, 2026, by the Reporting Person, with a plan end date of September 1, 2027.

2. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.12, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Remarks:

Reporting Person's title: EVP, Chief Legal Officer

	/s/ Latha Vairavan, as Attorney-in-Fact for Masaru Matsuda	09/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)